Source: International Congress 2016 – IPF treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Toby Maher (St. Albans, Hertfordshire, United Kingdom), Toby Maher, Kevin R. Flaherty, Yoshikazu Inoue, Luca Richeldi, Moisés Selman, Wibke Stansen, Susanne Stowasser, Athol Wells. No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib. Eur Respir J 2016; 48: Suppl. 60, 4959

Member's Comments

No comment yet.

Related content which might interest you: Diffusing capacity for carbon monoxide (DLco) may predict appearance of pulmonary hypertension in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Effect of baseline FVC on lung function decline with nintedanib in patients with IPF Source: International Congress 2015 – Treatment of IPF Year: 2015 Carbon monoxide diffusing capacity (DLCO) in COVID-19 survivors versus idiopathic pulmonary fibrosis (IPF): the pathogenetic features Source: Virtual Congress 2021 – A multidisciplinary approach to pulmonary rehabilitation and management of chronic respiratory diseases Year: 2021 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Effect of anti-acid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Anti-inflammatory effects of inhaled carbon monoxide in patients with COPD: a pilot study Source: Eur Respir J 2007; 30: 1131-1137 Year: 2007 Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib Source: International Congress 2015 – Treatment of IPF Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung Source: International Congress 2015 – Inflammation and remodelling in lung disease Year: 2015 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Using the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2015 – IIPs: orphan Year: 2015 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Effects of oxygen inhalation during exercise in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: Annual Congress 2010 - Gas exchange and paediatric exercise testing Year: 2010 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Exercise limitation in patients with interstitial lung disease independent from diffusion capacity (DLCO) Source: Annual Congress 2008 - Exercise: system responses Year: 2008